Effects of Tranexemic Acid Versus Norethisterone Acetate on Endometrial Vasculature .

NCT ID: NCT04290013

Last Updated: 2020-03-16

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-04-22
• Study Completion Date: 2020-12-31

Brief Summary

Heavy periods is a significant problem in reproductive age .It affects about a third of women in the childbearing period

Any of the following is considered to be heavy menstrual bleeding (Bleeding that lasts more than 7 days,Bleeding that soaks through one or more tampons or pads every hour for several hours in a row.Needing to wear more than one pad at a time to control menstrual flow.,Needing to change pads or tampons during the night or Menstrual flow with blood clots that are as big as a quarter or larger) .

Heavy periods can be caused by organic cause as fibroids, adenomyosis, polyps or they can be dysfunctional.Dysfunctional uterine bleeding is irregular uterine bleeding that occurs in the absence of recognisable pelvic pathology, general medical disease, or pregnancy. It reflects a disruption in the normal cyclic pattern of ovulatory hormonal stimulation to the endometrial lining.

Several treatment options include: hormonal treatment as norethisterone acetate,oral contraceptive pills, gonadotrophin releasing hormone analogue. ,tranexamic acid or non steroidal anti-inflammatory drugs.

The investigators plan to do a comparative study between norethisterone acetate and tranexamic acid regarding their control of the heavy periods as well as their effect on the uterine and endometrial vasculature.

Detailed Description

This is a Randomised controlled trial.The investigators will randomise 120 women who suffer from heavy periods (age range 35-49 years old) without organic cause (Dysfunctional bleeding ) into 2 groups, group A (60 women) : They will take norethisterone acetate 15 mg daily from day 5 to day 26 of the period for 3 months.

Group B (60 women): They will take 1 gm tranexemic acid three times daily from the start of menstrual period up to 5 days.The dose might be increased per day (Not more than 4 gm per day).

The investigators will check endometrial thickness, endometrial volume, uterine artery Doppler indices as well as endometrial and subendometrial indices before starting the treatment and 3 months afterwards.

Conditions

Dysfunctional Uterine Bleeding

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

norethisterone -women with Dysfunctional uterine bleeding

Group Type: EXPERIMENTAL

norethisterone acetate

Intervention Type: DRUG

norethisterone acetate 15 mg daily from day 5 of the cycle to day 26.

tranexemic acid-women with Dysfunctional uterine bleeding

Group Type: EXPERIMENTAL

tranexamic acid tablets

Intervention Type: DRUG

tranexemic acid 1 gm three times daily from the first day of the menstrual cycle up to 5 days .The dose can be increased but not exceeding 4 gm per day.

Interventions

norethisterone acetate

norethisterone acetate 15 mg daily from day 5 of the cycle to day 26.

Intervention Type: DRUG

tranexamic acid tablets

tranexemic acid 1 gm three times daily from the first day of the menstrual cycle up to 5 days .The dose can be increased but not exceeding 4 gm per day.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age: 35-49 years old.
• Normal gynecologic and breast examination
• Women who have sterilization or husband is sterilized or accepts to use a suitable barrier contraception during the duration of the study.
• Heavy periods (were assessed by validated pictorial blood chart)
• Normal ultrasound, hysteroscopy and endometrial biopsy.
• Normal coagulation profile and thyroid function.
• No contraindication to tranexamic acid or Norethisterone acetate : allergy,History of arterial or venous thromboembolic disease,Disturbance of liver function or Severe renal impairment.

Exclusion Criteria

• Women who are less than 35 years old or more than 49 years old.
• Women who had organic cause for heavy periods as uterine polypi,fibroids or endometriosis.
• Women taking hormonal preparation the month before starting the trial.
• Women with abnormal findings in pelvic ultrasound,hysteroscopy or endometrial biopsy.
• Women who suffer from uncontrolled diabetes or uncontrolled hypertension.
• Women with history of breast cancer or precancerous conditions.

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 49 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Cairo University

OTHER

Sponsor Role: lead

Responsible Party

Eman Elkattan

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Central Contacts

Eman Elkattan, MD,MRCOG,DFSRH

Role: CONTACT

emyelkattan@gmail.com

01212529213

Yasser Khamis, MD

Role: CONTACT

01125527555

Other Identifiers

Protocol 400

Identifier Type: -

Identifier Source: org_study_id